Signaling pathways governing tumor angiogenesis

Oncology

Volumn 81, Issue SUPPL. 1, 2011, Pages 24-29

  Sakurai, Toshiharu ^a   Kudo, Masatoshi ^a  

^a KINKI UNIVERSITY   (Japan)

Author keywords

c Jun N terminal kinase; Stromal cell; Vascular endothelial growth factor

Indexed keywords

ANGIOPOIETIN; ANGIOSTATIN; BEVACIZUMAB; CHEMOKINE; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; JAGGED1; MATRIX METALLOPROTEINASE; NOTCH RECEPTOR; PLATELET DERIVED GROWTH FACTOR; SMALL MOLECULE TRANSPORT AGENT; SOMATOMEDIN; SORAFENIB; STRESS ACTIVATED PROTEIN KINASE; SUNITINIB; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN E; VASCULOTROPIN RECEPTOR;

ANTIANGIOGENIC ACTIVITY; BLOOD VESSEL DIAMETER; BLOOD VESSEL PERMEABILITY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; DRUG TARGETING; ENDOTHELIUM CELL; EPIGENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHANGIOGENESIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANGIOPOIETINS; CALCIUM-BINDING PROTEINS; CHEMOKINES; FIBROBLAST GROWTH FACTORS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MATRIX METALLOPROTEINASES; MEMBRANE PROTEINS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, TIE; SIGNAL TRANSDUCTION; STROMAL CELLS; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 84855328537     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000333256     Document Type: Review

References (73)

1. Folkman J, Kalluri R: Cancer without disease. Nature 2004;427:787. (Pubitemid 38297724)
2. Kerbel R, Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-739. (Pubitemid 37328908)
3. Mueller MM, Fusenig NE: Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004;4:839-849. (Pubitemid 39472951)
4. Budhu A, Forgues M, Ye QH, et al: Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006;10:99-111. (Pubitemid 44202603)
5. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003;9:669-676. (Pubitemid 36749215)
6. Grothey A, Galanis E: Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009;6:507-518.
7. Sakurai T, Maeda S, Chang L, Karin M: Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci USA 2006;103:10544-10551. (Pubitemid 44078014)
8. Peinado H, Olmeda D, Cano A: Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 2007;7:415-428. (Pubitemid 46809165)
9. Gonzalez-Moreno O, Lecanda J, Green JE, Segura V, Catena R, Serrano D, Calvo A: VEGF elicits epithelial-mesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop. Exp Cell Res 2010;316:554-567.
10. Grothey A, Ellis LM: Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Cancer J 2008;14:170-177.
11. Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-1027. (Pubitemid 46202320)
12. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
13. Ferrara N, Hillan KJ, Gerber HP, Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400. (Pubitemid 38618122)
14. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134. (Pubitemid 46089673)
15. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124. (Pubitemid 46089672)
16. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342. (Pubitemid 38702844)
17. Sandler A, Gray R, Perry MC, Brahmer J, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550. (Pubitemid 44917502)
18. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
19. Kudo M, Ueshima K: Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan. Oncology 2010;78(suppl 1):154-166.
20. Bergers G, Hanahan D: Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.
21. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-239.
22. Pàez-Ribes M, Allen E, Hudock J, Takeda T, et al: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-231.
23. Huang J, Soffer SZ, Kim ES, et al: Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol Cancer Res 2004;2:36-42. (Pubitemid 38167106)
24. Kerbel RS: Molecular and physiologic mechanisms of drug resistance in cancer: an overview. Cancer Metastasis Rev 2001;20:1-2.
25. Shojaei F, Wu X, Malik AK, et al: Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 2007;25:911-920. (Pubitemid 47236916)
26. De Palma M, Venneri MA, Galli R, et al: Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005;8:211-226. (Pubitemid 41317592)
27. DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, Coussens LM: CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009;16:91-102.
28. Qian BZ, Pollard JW: Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141:39-51.
29. Cao Y, Cao R, Hedlund EM: R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways. J Mol Med 2008;86:785-789.
30. Korc M, Friesel RE: The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets 2009;9:639-651.
31. Maciag T, Mehlman T, Friesel R, Schreiber AB: Heparin binds endothelial cell growth factor, the principal endothelial cell mitogen in bovine brain. Science 1984;225:932-935. (Pubitemid 14064174)
32. Abraham JA, Mergia A, Whang JL, et al: Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor. Science 1986;233:545-548. (Pubitemid 16019907)
33. Bikfalvi A, Klein S, Pintucci G, Rifkin DB: Biological roles of fibroblast growth factor-2. Endocr Rev 1997;18:26-45. (Pubitemid 27076454)
34. Beenken A, Mohammadi M: The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009;8:235-253.
35. Lindner V, Majack RA, Reidy MA: Basic fibroblast growth factor stimulates endothelial regrowth and proliferation in denuded arteries. J Clin Invest 1990;85:2004-2008. (Pubitemid 20192979)
36. Wang D, Huang HJ, Kazlauskas A, Cavenee WK: Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res 1999;59:1464-1472. (Pubitemid 29160112)
37. Lindahl P, Johansson BR, Levéen P, Betsholtz C: Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997;277:242-245. (Pubitemid 27446080)
38. Andrae J, Gallini R, Betsholtz C: Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008;22:1276-1312. (Pubitemid 351717519)
39. Blobe GC, Schiemann WP, Lodish HF: Role of transforming growth factor beta in human disease. N Engl J Med 2000;342:1350-1358. (Pubitemid 30408720)
40. Carmeliet P: Angiogenesis in health and disease. Nat Med 2003;9:653-660.
41. Augustin HG, Koh GY, Thurston G, Alitalo K: Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009;10:165-177.
42. Saharinen P, Bry M, Alitalo K: How do angiopoietins Tie in with vascular endothelial growth factors? Curr Opin Hematol 2010;17:198-205.
43. Chae SS, Kamoun WS, Farrar CT, et al: Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin Cancer Res 2010;16:3618-3627.
44. Brown JL, Cao ZA, Pinzon-Ortiz M, et al: A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol Cancer Ther 2010;9:145-156.
45. Hashizume H, Falcón BL, Kuroda T, et al: Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 2010;70:2213-2223.
46. Oliner J, Min H, Leal J, et al: Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004;6:507-516. (Pubitemid 39469986)
47. De Palma M, Venneri MA, Roca C, Naldini L: Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med 2003;9:789-795. (Pubitemid 36749231)
48. Mantovani A, Sica A: Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010;22:231-237.
49. Pucci F, Venneri MA, Biziato D, et al: A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood 'resident' monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood 2009;114:901-914.
50. Kioi M, Vogel H, Schultz G, et al: Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 2010;120:694-705.
51. Thurston G, Kitajewski J: VEGF and Delta-Notch: interacting signalling pathways in tumour angiogenesis. Br J Cancer 2008;99:1204-1209.
52. Hellström M, Phng LK, Hofmann JJ, et al: Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007;445:776-780. (Pubitemid 46279716)
53. Noguera-Troise I, Daly C, Papadopoulos NJ, et al: Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006;444:1032-1037. (Pubitemid 46018516)
54. Ridgway J, Zhang G, Wu Y, et al: Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006;444:1083-1087. (Pubitemid 46018529)
55. Zeng Q, Li S, Chepeha DB, et al: Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell 2005;8:13-23. (Pubitemid 40991811)
56. Rundhaug JE: Matrix metalloproteinases, angiogenesis, and cancer. Clin Cancer Res 2003;9:551-554.
57. Bergers G, Brekken R, McMahon G, et al: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-744.
58. O'Reilly MS, Wiederschain D, Stetler-Stevenson WG, et al: Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem 1999;274:29568-29571.
59. Gialeli C, Theocharis AD, Karamanos NK: Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011;278:16-27.
60. Wen W, Moses MA, Wiederschain D, Arbiser JL, Folkman J: The generation of endostatin is mediated by elastase. Cancer Res 1999;59:6052-6056. (Pubitemid 30035619)
61. Keane MP, Belperio JA, Xue YY, Burdick MD, Strieter RM: Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J Immunol 2004;172:2853-2860. (Pubitemid 38263670)
62. Mestas J, Burdick MD, Reckamp K, et al: The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. J Immunol 2005;175:5351-5357. (Pubitemid 41456421)
63. Wang D, Wang H, Brown J, et al: CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med 2006;203:941-951.
64. Luan J, Shattuck-Brandt R, Haghnegahdar H, et al: Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression. J Leukoc Biol 1997;62:588-597. (Pubitemid 27519769)
65. White ES, Flaherty KR, Carskadon S, et al: Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res 2003;9:853-860. (Pubitemid 36182624)
66. Arenberg DA, Kunkel SL, Polverini PJ, Glass M, Burdick MD, Strieter RM: Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest 1996;97:2792-2802. (Pubitemid 26197092)
67. Kitadai Y, Haruma K, Sumii K, et al: Expression of interleukin-8 correlates with vascularity in human gastric carcinomas. Am J Pathol 1998;152:93-100. (Pubitemid 28028050)
68. Mizukami Y, Jo WS, Duerr EM, et al: Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med 2005;11:992-997. (Pubitemid 41294446)
69. Salcedo R, Ponce ML, Young HA, et al: Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000;96:34-40. (Pubitemid 30456447)
70. Maione TE, Gray GS, Petro J, et al: Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990;247:77-79.
71. Gupta SK, Singh JP: Inhibition of endothelial cell proliferation by platelet factor-4 involves a unique action on S phase progression. J Cell Biol 1994;127:1121-1127. (Pubitemid 24355998)
72. Romagnani P, Annunziato F, Lasagni L, et al: Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Invest 2001;107:53-63. (Pubitemid 32047414)
73. Streubel B, Chou A, Huber D, et al: Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 2004;351:250-259. (Pubitemid 38916042)